Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration

The localization of i.p. injected, radioiodine conjugated monoclonal antibody HMFG2 was studied in 18 patients with ovarian carcinoma. Patients were injected i.p. at time points up to 168 h before laparotomy, at which time tumor, ascites, normal tissue, and blood samples were removed and the contain...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1987-09, Vol.47 (17), p.4719-4723
Hauptverfasser: WARD, B. G, MATHER, S. J, HAWKINS, L. R, CROWTHER, M. E, SHEPHERD, J. H, GRANOWSKA, M, BRITTON, K. E, SLEVIN, M. L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4723
container_issue 17
container_start_page 4719
container_title Cancer research (Chicago, Ill.)
container_volume 47
creator WARD, B. G
MATHER, S. J
HAWKINS, L. R
CROWTHER, M. E
SHEPHERD, J. H
GRANOWSKA, M
BRITTON, K. E
SLEVIN, M. L
description The localization of i.p. injected, radioiodine conjugated monoclonal antibody HMFG2 was studied in 18 patients with ovarian carcinoma. Patients were injected i.p. at time points up to 168 h before laparotomy, at which time tumor, ascites, normal tissue, and blood samples were removed and the contained radioactivity measured. In the first 10 patients, localization was compared with that of a simultaneously injected irrelevant (nonspecific) antibody (UJ13A) of the same immunoglobulin class and, in the subsequent 8 patients, with HMFG2 administered i.v. After i.p. injection, HMFG2-radioiodine was found in concentrations of 0.0001-0.0030% of the injected amount per gram in solid tumor, 0.0363-0.02560%/g in ascites, 0.0003-0.0017%/g in blood, and 0.001-0.0012%/g in normal tissue. Tumor:normal tissue ratios of 0.9-10.0 and tumor:blood ratios of 0.3-4.0 were seen up to 168 h after injection. Localization of the HMFG2 conjugate was consistently greater than that of the irrelevant antibody. For solid tumor, the i.v. route of administration resulted in consistently higher absolute levels of HMFG2 conjugate uptake but tumor:blood and tumor:normal tissue ratios were similar. On the other hand the i.p. route of administration offered consistent advantages of 4- to 71-fold over the i.v. route when HMFG2 conjugate localization on ascites cells was examined. Ascites:normal tissue and ascites:blood ratios of up to 512 and 448, respectively, were achieved. After i.p. injection, radioiodine was cleared from the body exponentially with a half-life of 50 h. Maximum circulating blood levels of 8.6 +/- 2.0% injected activity were seen at 48 h and these then decreased with a t 1/2 value of 38 h. Over 80% of injected activity was cleared in the urine as nonprotein bound iodine by 168 h.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77666322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77666322</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-6b381e86a4926d79c3ead35ea5b1568373492bb32a331325f3d18a3709bbc1dc3</originalsourceid><addsrcrecordid>eNo9kM1KAzEUhQdRav15BCELcTcwyW0yU3dStAoVN7oud5JbmzKT1CRTqI_kU5picXU5nMN3D-ekGHMJTVlPJvK0GFdV1ZRyUovz4iLGTZaSV3JUjEAJzlUzLn4WXmNnvzFZ75hfsYDGeuuNdcS0d5vhExMZljxLa2K9d1533mHH0CXberNnz69Pc8GsY-uhx8zYYbD5agzaOt_jPcMYKcaeXDp8sC4F3JHzQ8wQ86e3FGzyjjI4-CFRPCTR9NbZmO1Du6vibIVdpOvjvSw-nh7fZ8_l4m3-MntYlGuhpqlULTScGoWTqVCmnmogNCAJZculaqCGbLQtCATgIOQKDG8Q6mratpobDZfF3R93G_zXQDEtexs1dR06yp2Xda2UAiFy8OYYHNqezHIbbI9hvzyOm_3bo48xj7wK6LSN_7HMAcUr-AW4wYfO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77666322</pqid></control><display><type>article</type><title>Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>WARD, B. G ; MATHER, S. J ; HAWKINS, L. R ; CROWTHER, M. E ; SHEPHERD, J. H ; GRANOWSKA, M ; BRITTON, K. E ; SLEVIN, M. L</creator><creatorcontrib>WARD, B. G ; MATHER, S. J ; HAWKINS, L. R ; CROWTHER, M. E ; SHEPHERD, J. H ; GRANOWSKA, M ; BRITTON, K. E ; SLEVIN, M. L</creatorcontrib><description>The localization of i.p. injected, radioiodine conjugated monoclonal antibody HMFG2 was studied in 18 patients with ovarian carcinoma. Patients were injected i.p. at time points up to 168 h before laparotomy, at which time tumor, ascites, normal tissue, and blood samples were removed and the contained radioactivity measured. In the first 10 patients, localization was compared with that of a simultaneously injected irrelevant (nonspecific) antibody (UJ13A) of the same immunoglobulin class and, in the subsequent 8 patients, with HMFG2 administered i.v. After i.p. injection, HMFG2-radioiodine was found in concentrations of 0.0001-0.0030% of the injected amount per gram in solid tumor, 0.0363-0.02560%/g in ascites, 0.0003-0.0017%/g in blood, and 0.001-0.0012%/g in normal tissue. Tumor:normal tissue ratios of 0.9-10.0 and tumor:blood ratios of 0.3-4.0 were seen up to 168 h after injection. Localization of the HMFG2 conjugate was consistently greater than that of the irrelevant antibody. For solid tumor, the i.v. route of administration resulted in consistently higher absolute levels of HMFG2 conjugate uptake but tumor:blood and tumor:normal tissue ratios were similar. On the other hand the i.p. route of administration offered consistent advantages of 4- to 71-fold over the i.v. route when HMFG2 conjugate localization on ascites cells was examined. Ascites:normal tissue and ascites:blood ratios of up to 512 and 448, respectively, were achieved. After i.p. injection, radioiodine was cleared from the body exponentially with a half-life of 50 h. Maximum circulating blood levels of 8.6 +/- 2.0% injected activity were seen at 48 h and these then decreased with a t 1/2 value of 38 h. Over 80% of injected activity was cleared in the urine as nonprotein bound iodine by 168 h.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 3621168</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - analysis ; Biological and medical sciences ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Injections, Intraperitoneal ; Injections, Intravenous ; Iodine Radioisotopes ; Kinetics ; Medical sciences ; Ovarian Neoplasms - immunology ; Tumors</subject><ispartof>Cancer research (Chicago, Ill.), 1987-09, Vol.47 (17), p.4719-4723</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7763610$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3621168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WARD, B. G</creatorcontrib><creatorcontrib>MATHER, S. J</creatorcontrib><creatorcontrib>HAWKINS, L. R</creatorcontrib><creatorcontrib>CROWTHER, M. E</creatorcontrib><creatorcontrib>SHEPHERD, J. H</creatorcontrib><creatorcontrib>GRANOWSKA, M</creatorcontrib><creatorcontrib>BRITTON, K. E</creatorcontrib><creatorcontrib>SLEVIN, M. L</creatorcontrib><title>Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>The localization of i.p. injected, radioiodine conjugated monoclonal antibody HMFG2 was studied in 18 patients with ovarian carcinoma. Patients were injected i.p. at time points up to 168 h before laparotomy, at which time tumor, ascites, normal tissue, and blood samples were removed and the contained radioactivity measured. In the first 10 patients, localization was compared with that of a simultaneously injected irrelevant (nonspecific) antibody (UJ13A) of the same immunoglobulin class and, in the subsequent 8 patients, with HMFG2 administered i.v. After i.p. injection, HMFG2-radioiodine was found in concentrations of 0.0001-0.0030% of the injected amount per gram in solid tumor, 0.0363-0.02560%/g in ascites, 0.0003-0.0017%/g in blood, and 0.001-0.0012%/g in normal tissue. Tumor:normal tissue ratios of 0.9-10.0 and tumor:blood ratios of 0.3-4.0 were seen up to 168 h after injection. Localization of the HMFG2 conjugate was consistently greater than that of the irrelevant antibody. For solid tumor, the i.v. route of administration resulted in consistently higher absolute levels of HMFG2 conjugate uptake but tumor:blood and tumor:normal tissue ratios were similar. On the other hand the i.p. route of administration offered consistent advantages of 4- to 71-fold over the i.v. route when HMFG2 conjugate localization on ascites cells was examined. Ascites:normal tissue and ascites:blood ratios of up to 512 and 448, respectively, were achieved. After i.p. injection, radioiodine was cleared from the body exponentially with a half-life of 50 h. Maximum circulating blood levels of 8.6 +/- 2.0% injected activity were seen at 48 h and these then decreased with a t 1/2 value of 38 h. Over 80% of injected activity was cleared in the urine as nonprotein bound iodine by 168 h.</description><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - analysis</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Injections, Intraperitoneal</subject><subject>Injections, Intravenous</subject><subject>Iodine Radioisotopes</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Ovarian Neoplasms - immunology</subject><subject>Tumors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1KAzEUhQdRav15BCELcTcwyW0yU3dStAoVN7oud5JbmzKT1CRTqI_kU5picXU5nMN3D-ekGHMJTVlPJvK0GFdV1ZRyUovz4iLGTZaSV3JUjEAJzlUzLn4WXmNnvzFZ75hfsYDGeuuNdcS0d5vhExMZljxLa2K9d1533mHH0CXberNnz69Pc8GsY-uhx8zYYbD5agzaOt_jPcMYKcaeXDp8sC4F3JHzQ8wQ86e3FGzyjjI4-CFRPCTR9NbZmO1Du6vibIVdpOvjvSw-nh7fZ8_l4m3-MntYlGuhpqlULTScGoWTqVCmnmogNCAJZculaqCGbLQtCATgIOQKDG8Q6mratpobDZfF3R93G_zXQDEtexs1dR06yp2Xda2UAiFy8OYYHNqezHIbbI9hvzyOm_3bo48xj7wK6LSN_7HMAcUr-AW4wYfO</recordid><startdate>19870901</startdate><enddate>19870901</enddate><creator>WARD, B. G</creator><creator>MATHER, S. J</creator><creator>HAWKINS, L. R</creator><creator>CROWTHER, M. E</creator><creator>SHEPHERD, J. H</creator><creator>GRANOWSKA, M</creator><creator>BRITTON, K. E</creator><creator>SLEVIN, M. L</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19870901</creationdate><title>Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration</title><author>WARD, B. G ; MATHER, S. J ; HAWKINS, L. R ; CROWTHER, M. E ; SHEPHERD, J. H ; GRANOWSKA, M ; BRITTON, K. E ; SLEVIN, M. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-6b381e86a4926d79c3ead35ea5b1568373492bb32a331325f3d18a3709bbc1dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - analysis</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Injections, Intraperitoneal</topic><topic>Injections, Intravenous</topic><topic>Iodine Radioisotopes</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Ovarian Neoplasms - immunology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WARD, B. G</creatorcontrib><creatorcontrib>MATHER, S. J</creatorcontrib><creatorcontrib>HAWKINS, L. R</creatorcontrib><creatorcontrib>CROWTHER, M. E</creatorcontrib><creatorcontrib>SHEPHERD, J. H</creatorcontrib><creatorcontrib>GRANOWSKA, M</creatorcontrib><creatorcontrib>BRITTON, K. E</creatorcontrib><creatorcontrib>SLEVIN, M. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WARD, B. G</au><au>MATHER, S. J</au><au>HAWKINS, L. R</au><au>CROWTHER, M. E</au><au>SHEPHERD, J. H</au><au>GRANOWSKA, M</au><au>BRITTON, K. E</au><au>SLEVIN, M. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1987-09-01</date><risdate>1987</risdate><volume>47</volume><issue>17</issue><spage>4719</spage><epage>4723</epage><pages>4719-4723</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>The localization of i.p. injected, radioiodine conjugated monoclonal antibody HMFG2 was studied in 18 patients with ovarian carcinoma. Patients were injected i.p. at time points up to 168 h before laparotomy, at which time tumor, ascites, normal tissue, and blood samples were removed and the contained radioactivity measured. In the first 10 patients, localization was compared with that of a simultaneously injected irrelevant (nonspecific) antibody (UJ13A) of the same immunoglobulin class and, in the subsequent 8 patients, with HMFG2 administered i.v. After i.p. injection, HMFG2-radioiodine was found in concentrations of 0.0001-0.0030% of the injected amount per gram in solid tumor, 0.0363-0.02560%/g in ascites, 0.0003-0.0017%/g in blood, and 0.001-0.0012%/g in normal tissue. Tumor:normal tissue ratios of 0.9-10.0 and tumor:blood ratios of 0.3-4.0 were seen up to 168 h after injection. Localization of the HMFG2 conjugate was consistently greater than that of the irrelevant antibody. For solid tumor, the i.v. route of administration resulted in consistently higher absolute levels of HMFG2 conjugate uptake but tumor:blood and tumor:normal tissue ratios were similar. On the other hand the i.p. route of administration offered consistent advantages of 4- to 71-fold over the i.v. route when HMFG2 conjugate localization on ascites cells was examined. Ascites:normal tissue and ascites:blood ratios of up to 512 and 448, respectively, were achieved. After i.p. injection, radioiodine was cleared from the body exponentially with a half-life of 50 h. Maximum circulating blood levels of 8.6 +/- 2.0% injected activity were seen at 48 h and these then decreased with a t 1/2 value of 38 h. Over 80% of injected activity was cleared in the urine as nonprotein bound iodine by 168 h.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>3621168</pmid><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1987-09, Vol.47 (17), p.4719-4723
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_77666322
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - analysis
Biological and medical sciences
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Injections, Intraperitoneal
Injections, Intravenous
Iodine Radioisotopes
Kinetics
Medical sciences
Ovarian Neoplasms - immunology
Tumors
title Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Localization%20of%20radioiodine%20conjugated%20to%20the%20monoclonal%20antibody%20HMFG2%20in%20human%20ovarian%20carcinoma:%20assessment%20of%20intravenous%20and%20intraperitoneal%20routes%20of%20administration&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=WARD,%20B.%20G&rft.date=1987-09-01&rft.volume=47&rft.issue=17&rft.spage=4719&rft.epage=4723&rft.pages=4719-4723&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E77666322%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77666322&rft_id=info:pmid/3621168&rfr_iscdi=true